APC and colorectal carcinoma: Recently, the antiparasitic drug nitazoxanide (NTZ), approved by the US Food and Drug Administration (FDA) for use in humans, has been reported to antagonize Wnt/β-catenin signaling by abrogating β-catenin independent of GSK-3β and APC [13], indicating the potential therapeutic value of NTZ in APC-mutated or β-catenin-mutated CRC.